Valuation: C4 Therapeutics, Inc.

Market Cap 415M 371M 342M 309M 578M 39.37B 589M 4.07B 1.64B 20.71B 1.56B 1.52B 65.3B P/E 2026 *
-4.02x
P/E 2027 * -3.68x
Enterprise Value 333M 299M 275M 249M 465M 31.65B 474M 3.27B 1.31B 16.65B 1.25B 1.22B 52.5B EV / Sales 2026 *
12.7x
EV / Sales 2027 * 13.3x
Free-Float
99.16%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: C4 Therapeutics, Inc.

1 day+2.12%
1 week+10.13%
Current month+1.20%
1 month+1.20%
3 months-7.92%
6 months+19.08%
Current year+76.44%
1 week 2.94
Extreme 2.94
3.53
1 month 2.59
Extreme 2.59
3.53
Current year 1.69
Extreme 1.6901
5.17
1 year 1.69
Extreme 1.6901
5.17
3 years 1.06
Extreme 1.06
11.88
5 years 1.06
Extreme 1.06
48.75
10 years 1.06
Extreme 1.06
51.21
Manager TitleAgeSince
Chief Executive Officer 55 02/10/2020
Director of Finance/CFO 49 18/09/2023
Chief Tech/Sci/R&D Officer 56 28/10/2024
Director TitleAgeSince
Director/Board Member 74 01/12/2015
Director/Board Member 55 14/09/2020
Director/Board Member 55 16/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
1/10/26 Free

Founder

3,662 0.0030%
1/10/26 Free

Director

4,618 0.0038%
18/9/26 Exercice

Chief Financial Officer

9,025 0.0073%
Change 5-day change 1-year change 3-year change Capi.($)
+2.12%+10.13%+36.99%+123.18% 415M
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average +0.52%+7.80%+46.77%+198.01% 39.48B
Weighted average by Cap. +0.18%+5.45%+48.49%+186.06%

Financials

2026 *2027 *
Net sales 26.32M 23.57M 21.68M 19.64M 36.72M 2.5B 37.41M 259M 104M 1.31B 98.77M 96.67M 4.15B 22.43M 20.09M 18.48M 16.74M 31.29M 2.13B 31.88M 220M 88.45M 1.12B 84.17M 82.38M 3.53B
Net income -111M -99.29M -91.33M -82.75M -155M -10.53B -158M -1.09B -437M -5.54B -416M -407M -17.46B -141M -126M -116M -105M -196M -13.37B -200M -1.38B -555M -7.03B -529M -517M -22.18B
Net Debt -81.29M -72.8M -66.97M -60.68M -113M -7.72B -116M -799M -321M -4.06B -305M -299M -12.8B -117M -105M -96.51M -87.45M -163M -11.12B -167M -1.15B -462M -5.85B -440M -430M -18.45B
Projected Income Statement - Annual - C4 Therapeutics, Inc.
Logo C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Employees
104
Date Price Change Volume
30/10/26 USD 3.370 +2.12% 2,354,093
29/10/26 USD 3.300 -2.80% 2,715,031
28/10/26 USD 3.395 +5.76% 4,110,813
27/10/26 USD 3.210 +7.72% 4,119,734
26/10/26 USD 2.980 -2.61% 3,179,137
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - C4 Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.370USD
Average target price
12.62USD
Spread / Average Target
+274.63%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - C4 Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CCCC Stock